Eculizumab is a promising therapeutic option in HSCT recipients with high-risk TMA.
Eculizumab clearance in HSCT recipients depends on TMA disease activity.
Plasma sC5b-9 concentration can be used to determine eculizumab dosing regimen.
CH50 monitoring aids decision to discontinue therapy when TMA is controlled.
PK/PD-guided eculizumab therapy improves survival in HSCT recipients with TMA.